UroGen Pharma Ltd. (URGN)
UroGen Pharma Statistics
Share Statistics
UroGen Pharma has 46.11M shares outstanding. The number of shares has increased by 12.07% in one year.
| 46.11M |
| 12.07% |
| 9.23% |
| 84.16% |
| n/a |
| 1,336 |
| 0.11% |
Short Selling Information
The latest short interest is 5.59M, so 12.12% of the outstanding shares have been sold short.
| 5.59M |
| 12.12% |
| 12.37% |
| 8.16 |
Valuation Ratios
The PE ratio is -3.6 and the forward PE ratio is -4.01. UroGen Pharma's PEG ratio is 0.22.
| -3.6 |
| -4.01 |
| 5.05 |
| 0.4 |
| -51.87 |
| -4.7 |
| 0.22 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for UroGen Pharma.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 6.01, with a Debt / Equity ratio of -14.02.
| 6.01 |
| 5.81 |
| -14.02 |
| -1.12 |
| -1.27 |
| -7.73 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| $386,316.24 |
| $-542,196.58 |
| 234 |
| 0.32 |
| 0.96 |
Taxes
| 2.83M |
| -2.28% |
Stock Price Statistics
The stock price has increased by -61.11% in the last 52 weeks. The beta is 0.4, so UroGen Pharma's price volatility has been higher than the market average.
| 0.4 |
| -61.11% |
| 8.98 |
| 11.09 |
| 36.25 |
| 1,265,946 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of 90.4M and earned -126.87M in profits. Earnings per share was -2.96.
| 90.4M |
| 81.52M |
| -96.78M |
| -126.87M |
| -110.33M |
| -111.52M |
| -2.96 |
Balance Sheet
The company has 171.99M in cash and 123.39M in debt, giving a net cash position of 48.6M.
| 171.99M |
| 123.39M |
| 48.6M |
| -806.22M |
| 247.62M |
| 195.18M |
Cash Flow
In the last 12 months, operating cash flow was -96.77M and capital expenditures -295K, giving a free cash flow of -97.06M.
| -96.77M |
| -295K |
| -97.06M |
| -2.26 |
Margins
Gross margin is 90.18%, with operating and profit margins of -107.06% and -140.35%.
| 90.18% |
| -107.06% |
| -137.22% |
| -140.35% |
| -122.05% |
| -107.06% |
| -107.37% |
Dividends & Yields
URGN does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Analyst Forecast
The average price target for URGN is $20, which is 289.9% higher than the current price. The consensus rating is "Buy".
| $20 |
| 289.9% |
| Buy |
| 7 |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Scores
| -4.48 |
| 1 |